Merck Kicks Off 2023 Curiosity Cube Mobile Lab Tour
Merck has kicked off its 2023 Curiosity Cube tour in Europe and North America. Merck, a leading science and technology company, has kicked off its […]
Articles by MaP
Bayer’s Grants4Ag Program Awards 21 Crop Science Research Grants for 2023
This year’s focus lies on research to support sustainability and the development of next-generation genomic tools in agriculture / Researchers will receive funding and mentorship […]
Beactica Therapeutics and Oscotec mutually agree to conclude oncology collaboration
Beactica Therapeutics AB, the Swedish precision oncology company, and Oscotec Inc. (039200: KOSDAQ), the Korean drug development company, today announced that they have mutually agreed […]
CONCORDANCE HEALTHCARE SOLUTIONS SELECTS LOCUS ROBOTICS AMRs TO DELIVER HIGH VOLUME ORDER FULFILLMENT FOR THE HEALTHCARE INDUSTRY
Robotics automation to deliver robust, scalable solution for high-volume healthcare fulfilment centers Concordance Healthcare Solutions LLC, one of the largest, independent healthcare distributors in the […]
BioNTech and DualityBio Form Global Strategic Partnership to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics for Solid Tumors
BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Duality Biologics (Suzhou) Co. Ltd. (“DualityBio”), a clinical-stage biotech company focusing on the discovery and development of next generation […]
Internationally renowned experts form independent Bayer Bioethics Council
Bayer establishes Bioethics Council Experts from different academic disciplines to provide broad external perspective and guidance on complex bioethical questions related to emerging life […]
SciBase and Schweiger Dermatology Group partner to advance skin cancer detection in select New Jersey locations
SciBase Holding AB (“SciBase”) (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders announced today that they have entered into a collaboration agreement […]
BioNTech Announces New ADS Repurchase Program
BioNTech SE (Nasdaq: BNTX, “BioNTech” or the “Company”) today announced that it has entered into a new share repurchase program (the “Program”), pursuant to which the […]
Merck Announces Expanded Partnership with Beyond Benign to Increase Global Access to Green Chemistry Education
Merck, has entered an expanded partnership with global green chemistry education nonprofit Beyond Benign. • Helps grow Beyond Benign’s flagship programs to 175 institutions and […]
Bayer expands global clinical program for darolutamide in prostate cancer
Bayer expands global clinical program for darolutamide in prostate cancer Phase III study ARASTEP initiated in hormone-sensitive prostate cancer, in patients with high-risk biochemical […]
Sandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation
Biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation (HCF) approved for seven indications of reference medicine Humira®* With this approval, Sandoz adalimumab HCF biosimilar will offer US patients […]
Pigs as Organ Donors – New Findings on the Prevention of Retrovirus Infections
Quote Professor Ralf Tönjes Video Player Intensive research is being carried out to enable the transplantation of organs from specially bred pigs to humans. However, […]
Nubeqa™ (darolutamide) approved for additional prostate cancer indication in China Nubeqa™ now approved for metastatic hormone-sensitive prostate cancer as well as non-metastatic castration-resistant prostate cancer
Additional indication based on data from the pivotal Phase III ARASENS trial The Chinese National Medical Products Administration (NMPA) has approved the oral androgen receptor […]
New four year data for Roche’s Evrysdi reinforce long-term efficacy and safety profile in some of the most severely affected people with types 2 and 3 spinal muscular atrophy (SMA)
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new long-term data for Evrysdi® (risdiplam) in a broad range of people aged 2-25 years with spinal […]
Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset
Novartis today presented new data which underscore the transformational and sustained benefit of Zolgensma® (onasemnogene abeparvovec), an essential one-time gene therapy for the treatment of spinal […]